A Decadal Exploration of Cutaneous Adverse Effects of FDA-Approved Cardiovascular Medications: Insights from 2013 to 2023.
| Autor: | Jallorina A; California University of Science and Medicine, Colton, CA, USA., Vij K; West Virginia School of Osteopathic Medicine, Lewisburg, WV, USA., Wan L; West Virginia School of Osteopathic Medicine, Lewisburg, WV, USA., Thomas J; West Virginia School of Osteopathic Medicine, Lewisburg, WV, USA., Drum D; California University of Science and Medicine, Colton, CA, USA., Glick SA; SUNY Downstate Health Sciences University, Department of Dermatology, Brooklyn, New York, USA.; Maimonides Medical Center, Department of Medicine, Brooklyn, New York, USA., Lee-Wong MF; Icahn School of Medicine at Mount Sinai, Division of Allergy and Clinical Immunology, Department of Medicine, New York, USA.; Maimonides Medical Center, Department of Medicine, Brooklyn, New York, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of cardiovascular pharmacology [J Cardiovasc Pharmacol] 2024 Dec 05. Date of Electronic Publication: 2024 Dec 05. |
| DOI: | 10.1097/FJC.0000000000001660 |
| Abstrakt: | Given the high prevalence of cardiovascular disease in the United States, there is a critical need for new medications to improve outcomes of these diseases. The U.S. Food and Drug Administration (FDA) has approved numerous medications that are able to effectively do so. While these drugs have significantly beneficial effects, just like any other medication, they can come with a multitude of unwanted side effects. It has been noted that cardiovascular drugs have been associated with a considerable number of dermatologic reactions. This review examines current literature on the various cutaneous manifestations of these adverse reactions. It focuses on these newly FDA-approved cardiovascular medications from 2013 to 2023, detailing both common and rare effects in the past decade. As more medications continue to enter the market, the necessity for awareness of more systemic side effects will continue to grow. This comprehensive review aims to guide clinicians in identifying drug-induced reactions in patients on these therapies. Competing Interests: Conflict of Interest Disclosure: All the authors have no conflicts of interest to declare. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|